Answers are grounded in this paper and cite their sources.
Chimeric antigen receptor-engineered natural killer (CAR-NK) cells combine major histocompatibility complex (MHC)-independent, CAR-mediated antigen recognition with the intrinsic cytotoxic mechanisms of NK cells. Among liver diseases, hepatocellular carcinoma (HCC) is currently the principal indication for which CAR-NK cell therapy has been investigated, whereas the application of CAR-NK cells in nonmalignant liver diseases remains largely conceptual. This review therefore focuses on the biological basis, cellular sources, CAR design principles, therapeutic targets, and translational development of CAR-NK cells for treating HCC, while also considering their prospective relevance to viral hepatitis, liver fibrosis, and autoimmune liver diseases. In HCC, GPC3, c-Met, EpCAM, B7-H3, and NKG2D ligands have been explored as potential targets, predominantly in preclinical studies. AFP-CAR-NK approaches remain exploratory and require construct-specific verification of the recognized antigenic form and any dependence on MHC presentation. However, the immunosuppressive hepatic tumor microenvironment, characterized by transforming growth factor beta (TGF-β) signaling, hypoxia, metabolic stress, suppressive myeloid cells, and immune checkpoint activation, remains a major barrier to effective trafficking, persistence, and cytotoxicity. Liver-adapted CAR-NK cell (LA-CAR-NK) strategies that involve cytokine armoring, chemokine receptor modification, checkpoint resistance, metabolic reprogramming, locoregional delivery, and combination therapy may help overcome these limitations. Cytokine armoring should incorporate control of expression level and duration, appropriate cell dosing, and safety switches to sustain antitumor activity while limiting excessive expansion and toxicity. We further compare CAR-NK and CAR-T cell platforms while emphasizing the lack of direct head-to-head evidence in HCC and the potentially complementary roles of these platforms according to disease stage, tumor burden, liver function, and treatment objectives. With respect to nonmalignant liver diseases, existing support derives mainly from theoretical considerations and indirect evidence from CAR-T cells and CAR-macrophages (CAR-M). Further studies are needed to establish the clinical utility of CAR-NK cell therapy in patients with HCC and to determine whether this platform can be safely and effectively extended to other liver diseases.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: